Latest & greatest articles for colorectal cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on colorectal cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on colorectal cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for colorectal cancer

21. British Society of Gastroenterology/Association of Coloproctology of Great Britain and Ireland/Public Health England post-polypectomy and post-colorectal cancer resection surveillance guidelines Full Text available with Trip Pro

Sussex Hospitals NHS Foundation Trust, Chichester, UK. 6 Colorectal surgery, Raigmore Hospital, Inverness, UK. 7 Gastroenterology, Cardiff and Vale NHS Trust, Cardiff, UK. 8 Histopathology, Nottingham University Hospitals, Nottingham, UK. 9 Family History of Bowel Cancer Clinic, West Middlesex University Hospital, London, UK. 10 Imperial College, London, UK. 11 Histopathology, University College London, London, UK. 12 Centre for Medical Imaging, UCL, London, UK. 13 Endoscopy, St Marks Hospital (...) Abstract These consensus guidelines were jointly commissioned by the British Society of Gastroenterology (BSG), the Association of Coloproctology of Great Britain and Ireland (ACPGBI) and Public Health England (PHE). They provide an evidence-based framework for the use of surveillance colonoscopy and non-colonoscopic colorectal imaging in people aged 18 years and over. They are the first guidelines that take into account the introduction of national bowel cancer screening. For the first time, they also

2020 EvidenceUpdates

22. FOLFOXIRI Plus Panitumumab As First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109)

FOLFOXIRI Plus Panitumumab As First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109) FOLFOXIRI Plus Panitumumab As First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109) - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go (...) your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error Add Cancel Add to My Bibliography My Bibliography Unable to load your delegates due to an error Add Cancel Actions Cite Share Permalink Copy Page navigation J Clin Oncol Actions , 37 (35), 3401-3411 2019 Dec 10 FOLFOXIRI Plus Panitumumab As First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109

2020 EvidenceUpdates

23. Endoscopic management of Lynch syndrome and of familial risk of colorectal cancer: European Society of Gastrointestinal Endoscopy (ESGE) Guideline

repair genes in hereditary nonpolyposis colorectal cancer patients with small bowel cancer: International Society for Gastrointestinal Hereditary Tumours Collaborative Study. Clinical Cancer Res 2006; 12: 3389–3393 [80] Rodriguez-Bigas MA, Vasen HF, Lynch HT et al. Characteristics of small bowel carcinoma in hereditary nonpolyposis colorectal carci- noma. International Collaborative Group on HNPCC. Cancer 1998; 83: 240–244 [81] SchulmannK,BraschFE,KunstmannEetal.HNPCC-associatedsmall bowel cancer (...) cancer mortality in first- degree relatives ofearly-onset colorectal cancer cases. Dis Colon Rectum 2002; 45: 681–686 [107] Kune GA, Kune S, Watson LF. The role of heredity in the etiologyof large bowel cancer: data from the Melbourne Colorectal Cancer Study. World J Surg 1989; 13: 124–129 ; discussion 9–31 [108] Samadder NJ, Smith KR, Hanson H et al. Increased riskofcolorectal canceramongfamilymembersofallages,regardlessofageofindex case at diagnosis. Clin Gastroenterol Hepatol 2015; 13: 2305–2311

2020 European Society of Gastrointestinal Endoscopy

24. Investigating the Effect of Self-Care Training on Life Expectancy and Quality of Life in Patients with Gastrointestinal Cancer under Radiotherapy. Full Text available with Trip Pro

Investigating the Effect of Self-Care Training on Life Expectancy and Quality of Life in Patients with Gastrointestinal Cancer under Radiotherapy. A huge amount of the efforts made by health teams is dedicated to caring for cancer patients. This study has aimed to investigate the effect of self-care training on life expectancy and quality of life (QOL) in patients with gastrointestinal cancer who were under radiotherapy.In this clinical trial, 50 patients were selected using the block (...) training improved the QOL and life expectancy of patients with gastrointestinal cancer who were under radiotherapy. Therefore, self-care training is recommended to improve the QOL and the life expectancy of cancer patients.

2019 Asia-Pacific journal of oncology nursing Controlled trial quality: uncertain

25. Colorectal cancer screening with faecal immunochemical testing, sigmoidoscopy or colonoscopy Full Text available with Trip Pro

Have inflammatory bowel disease Have hereditary syndromes that increase the risk of colorectal cancer, such as Lynch syndrome and familial adenomatous polyposis. Several factors influence individuals’ decisions whether to be screened, even when they are presented with the same information: Variation in an individual’s values and preferences A close balance of benefits versus harms and burdens (for example, for a baseline risk of 3%, FIT every two years results in five fewer deaths from colorectal (...) recommendations: an international comparison of high income countries . NHS. Bowel scope screening. . Navarro M , Nicolas A , Ferrandez A , Lanas A . Colorectal cancer population screening programs worldwide in 2016: An update . Levin TR , Corley DA , Jensen CD , et al . Effects of organized colorectal cancer screening on cancer incidence and mortality in a large community-based population . Cancer Research UK. Bowel cancer incidence statistics. . Danckert B FJ, Engholm G, Hansen HL, et al. NORDCAN: Cancer

2019 BMJ Rapid Recommendations

26. Bevacizumab (Zirabev) - colorectal cancer, non-small cell lung cancer, peritoneal cancer, glioblastoma

Bevacizumab (Zirabev) - colorectal cancer, non-small cell lung cancer, peritoneal cancer, glioblastoma Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity

2019 Health Canada - Drug and Health Product Register

27. Colorectal Cancer

of Colorectal Liver Metastases 111 7.4.3. Tumor Markers 113 7.4.4. Specific Diagnostics for Rectal Cancer 114 7.5. Surgical Therapy with Curative Intention 117 7.5.1. Intraoperative Staging 117 7.5.1.1. Intra-Operative Pathological Examination 117 7.5.2. Radical Surgical Therapy of Colon Cancer 118 7.5.2.1. Extent of Lymph Node Dissection: 118 7.5.2.2. Complete Mesocolic Excision (CME) 120 7.5.2.3. Local Ablative Therapies for Liver Metastases 121 7.5.2.3.1. Radio-Frequency Ablation (RFA) 121 7.5.2.3.2 (...) (Hereditary Non-Polyposis Colorectal Cancer) 135 7.7.8. Cancers in Familial Adenomatous Polyposis (FAP) 136 1.1 Editors © German Guideline Program in Oncology | Evidenced-based Guideline for Colorectal Cancer | Version 2.1 | Januar 2019 6 7.7.9. Cancers in Ulcerative Colitis 136 7.8. Postoperative Histopathological Examination 137 7.8.1. Cancer-Grading Based on MSI-H 137 7.8.2. Number of LN to be Removed 138 7.8.3. Relevance of Distance Between the Tumor Margin and Resection Area of the Mesocolon in Colon

2019 German Guideline Program in Oncology

28. Endoscopic surveillance after surgical or endoscopic resection for colorectal cancer

Endoscopic surveillance after surgical or endoscopic resection for colorectal cancer Endoscopic surveillance after surgical or endoscopic resection for colorectal cancer: European Society of Gastrointestinal Endoscopy (ESGE) and European Society of Digestive Oncology (ESDO) Guideline – European Society of Gastrointestinal Endoscopy (ESGE) +49-89-9077936-11 Menu DOI https://doi.org/10.1055/a-0831-2522 Endoscopy 2019; 51: 266–277 © Georg Thieme Verlag KG Stuttgart· New York Explore the ESGE (...) website Menu Contact us +49-89-9077936-0 Follow us © 2004 - 2019 European Society of Gastrointestinal Endoscopy (ESGE). All Rights Reserved. |

2019 European Society of Gastrointestinal Endoscopy

29. Endoscopic management of Lynch syndrome and of familial risk of colorectal cancer

Endoscopic management of Lynch syndrome and of familial risk of colorectal cancer Endoscopic management of Lynch syndrome and of familial risk of colorectal cancer: European Society of Gastrointestinal Endoscopy (ESGE) Guideline – European Society of Gastrointestinal Endoscopy (ESGE) +49-89-9077936-11 Menu DOI https://doi.org/10.1055/a-1016-4977 | Endoscopy 2019; 51:1082–1093 Published online: 9.10.2019 © Georg Thieme Verlag KG Stuttgart · New York Explore the ESGE website Menu Contact us +49 (...) -89-9077936-0 Follow us © 2004 - 2019 European Society of Gastrointestinal Endoscopy (ESGE). All Rights Reserved. |

2019 European Society of Gastrointestinal Endoscopy

30. Advanced imaging for detection and differentiation of colorectal neoplasia

Advanced imaging for detection and differentiation of colorectal neoplasia Advanced imaging for detection and differentiation of colorectal neoplasia: European Society of Gastrointestinal Endoscopy (ESGE) Guideline – Update 2019 – European Society of Gastrointestinal Endoscopy (ESGE) +49-89-9077936-11 Menu DOI https://doi.org/10.1055/a-1031-7657 | Endoscopy 2019; 51: 1155–1179 Published online: 11.11.2019 © Georg Thieme Verlag KG Stuttgart · New York Explore the ESGE website Menu Contact us +49 (...) -89-9077936-0 Follow us © 2004 - 2019 European Society of Gastrointestinal Endoscopy (ESGE). All Rights Reserved. |

2019 European Society of Gastrointestinal Endoscopy

31. Variation in post-colonoscopy colorectal cancer across colonoscopy providers in English National Health Service: population based cohort study. Full Text available with Trip Pro

for colonoscopies performed under the NHS bowel cancer screening programme (593/16 640, 3.6%), while they were higher for those conducted by non-NHS providers (187/2009, 9.3%). Rates were higher in women, in older age groups, and in people with inflammatory bowel disease or diverticular disease, in those with higher comorbidity scores, and in people with previous cancers. Substantial variation in rates among colonoscopy providers remained after adjustment for case mix.Wide variation exists in PCCRC-3yr rates (...) across NHS colonoscopy providers in England. The lowest incidence was seen in colonoscopies performed under the NHS bowel cancer screening programme. Quality improvement initiatives are needed to address this variation in rates and prevent colorectal cancer by enabling earlier diagnosis, removing premalignant polyps, and therefore improving outcomes.Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group

2019 BMJ

32. Screening for Colorectal Cancer in Asymptomatic Average-Risk Adults: A Guidance Statement From the American College of Physicians. Full Text available with Trip Pro

Screening for Colorectal Cancer in Asymptomatic Average-Risk Adults: A Guidance Statement From the American College of Physicians. The purpose of this guidance statement is to guide clinicians on colorectal cancer screening in average-risk adults.This guidance statement is derived from a critical appraisal of guidelines on screening for colorectal cancer in average-risk adults and the evidence presented in these guidelines. National guidelines published in English between 1 June 2014 and 28 May (...) should screen for colorectal cancer in average-risk adults between the ages of 50 and 75 years.Clinicians should select the colorectal cancer screening test with the patient on the basis of a discussion of benefits, harms, costs, availability, frequency, and patient preferences. Suggested screening tests and intervals are fecal immunochemical testing or high-sensitivity guaiac-based fecal occult blood testing every 2 years, colonoscopy every 10 years, or flexible sigmoidoscopy every 10 years plus

2019 Annals of Internal Medicine

33. Bowel cancer screening: imaging use

screening: imaging use Information about imaging practice standards for bowel cancer screening of individuals unsuitable for a colonoscopy. Published 1 November 2012 Last updated 14 October 2019 — From: Documents Ref: PHE publications gateway number: GW-810 HTML Details This publication explains the use of whole colon imaging as an alternative to a colonoscopy as part of the NHS Bowel Cancer Screening Programme ( 14 October 2019 Added new guidelines on CTC imaging in NHS bowel cancer screening. 1 (...) Bowel cancer screening: imaging use Bowel cancer screening: imaging use - GOV.UK GOV.UK uses cookies which are essential for the site to work. We also use non-essential cookies to help us improve government digital services. Any data collected is anonymised. By continuing to use this site, you agree to our use of cookies. Accept cookies You’ve accepted all cookies. You can at any time. Hide Search Register by 26 November to vote in the General Election on 12 December. Guidance Bowel cancer

2019 Public Health England

34. Phase II randomized clinical trial of endosonography and PET/CT versus clinical assessment only for follow-up after surgery for upper gastrointestinal cancer (EUFURO study) (Abstract)

Phase II randomized clinical trial of endosonography and PET/CT versus clinical assessment only for follow-up after surgery for upper gastrointestinal cancer (EUFURO study) Upper gastrointestinal malignancies have a poor prognosis. There is no consensus on how patients should be followed after surgery. The authors hypothesized that a structured follow-up programme including endoscopic ultrasonography (EUS) and [18 F]fluorodeoxyglucose (FDG) PET/CT would detect cancer recurrences, leading (...) chemotherapy (P = 0·028). Although survival after detection of recurrence in asymptomatic patients was significantly longer than that for symptomatic patients (P < 0·001), overall survival from date of surgery in the two treatment groups was comparable.Follow-up after surgery for upper gastrointestinal cancer with EUS and PET/CT leads to detection of more asymptomatic cancer recurrences and patients referred for treatment without prolonging overall survival. Registration number: NCT02209415 ( http

2019 EvidenceUpdates

35. Colorectal cancer. (Abstract)

Colorectal cancer. Several decades ago, colorectal cancer was infrequently diagnosed. Nowadays, it is the world's fourth most deadly cancer with almost 900 000 deaths annually. Besides an ageing population and dietary habits of high-income countries, unfavourable risk factors such as obesity, lack of physical exercise, and smoking increase the risk of colorectal cancer. Advancements in pathophysiological understanding have increased the array of treatment options for local and advanced disease (...) leading to individual treatment plans. Treatments include endoscopic and surgical local excision, downstaging preoperative radiotherapy and systemic therapy, extensive surgery for locoregional and metastatic disease, local ablative therapies for metastases, and palliative chemotherapy, targeted therapy, and immunotherapy. Although these new treatment options have doubled overall survival for advanced disease to 3 years, survival is still best for those with non-metastasised disease. As the disease

2019 Lancet

36. Colorectal cancer screening with faecal immunochemical testing, sigmoidoscopy or colonoscopy: a microsimulation modelling study. Full Text available with Trip Pro

Colorectal cancer screening with faecal immunochemical testing, sigmoidoscopy or colonoscopy: a microsimulation modelling study. To estimate benefits and harms of different colorectal cancer screening strategies, stratified by (baseline) 15-year colorectal cancer risk.Microsimulation modelling study using MIcrosimulation SCreening ANalysis-Colon (MISCAN-Colon).A parallel guideline committee (BMJ Rapid Recommendations) defined the time frame and screening interventions, including selection (...) of outcome measures.Norwegian men and women aged 50-79 years with varying 15-year colorectal cancer risk (1-7%).Four screening strategies were compared with no screening: biennial or annual faecal immunochemical test (FIT) or single sigmoidoscopy or colonoscopy at 100% adherence.Colorectal cancer mortality and incidence, burdens, and harms over 15 years of follow-up. The certainty of the evidence was assessed using the GRADE approach.Over 15 years of follow-up, screening individuals aged 50-79 at 3% risk

2019 BMJ

37. Occult Blood Detection Testing for Non-Colorectal Cancer Related Medical Conditions: Clinical Effectiveness

Occult Blood Detection Testing for Non-Colorectal Cancer Related Medical Conditions: Clinical Effectiveness Occult Blood Detection Testing for Non-Colorectal Cancer Related Medical Conditions: Clinical Effectiveness | CADTH.ca Find the information you need Occult Blood Detection Testing for Non-Colorectal Cancer Related Medical Conditions: Clinical Effectiveness Occult Blood Detection Testing for Non-Colorectal Cancer Related Medical Conditions: Clinical Effectiveness Last updated: April 15 (...) , 2019 Project Number: RA1026-000 Product Line: Research Type: Devices and Systems Report Type: Reference List Result type: Report Question What is the clinical effectiveness of the fecal immunochemical test in detecting medical conditions other than colorectal cancer where occult blood detection is needed? What is the clinical effectiveness of the guaiac fecal blood occult test in detecting medical conditions other than colorectal cancer where occult blood detection is needed? Key Message

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

38. Trifluridine and Tipiracil (Lonsurf) for Metastatic Colorectal Cancer Resubmission – Details

Strength 15 mg & 20 mg Tumour Type Gastrointestinal Indication Metastatic Colorectal Cancer Funding Request Treatment of adult patients with mCRC who have been previously treated with, or are not candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF biological agents, and, if RAS wild-type, anti-EGFR agents Review Status Notification to Implement Issued Pre Noc Submission No NOC Date January 25, 2018 Manufacturer Taiho Pharma Canada (...) Trifluridine and Tipiracil (Lonsurf) for Metastatic Colorectal Cancer Resubmission – Details Trifluridine and Tipiracil (Lonsurf) for Metastatic Colorectal Cancer Resubmission – Details | CADTH.ca Find the information you need Trifluridine and Tipiracil (Lonsurf) for Metastatic Colorectal Cancer Resubmission – Details Trifluridine and Tipiracil (Lonsurf) for Metastatic Colorectal Cancer Resubmission – Details Project Number pCODR 10173 Brand Name Lonsurf Generic Name Trifluridine and Tipiracil

2019 CADTH - Pan Canadian Oncology Drug Review

39. Guidelines for the management of hereditary colorectal cancer

neoplasia. ATZ: anal transitional zone. BSG: British Society of Gastroenterology. BSGM: British society of genetic medicine. CHRPE: congenital hypertrophy retinal pigmentation epithelium. CI: confidence intervals. COX-2: Cyclooxygenase-2 . CRC: colorectal cancer. CSSC: Clinical Services and Standards Committee. EHTG: European Hereditary Tumour Group. EOCRC: Early onset CRC. ESGE: European Society of Gastrointestinal Endoscopy. FAP: Familial adenomatous polyposis. FDR: First-degree relative. FH: family (...) ; Strength of recommendation: strong) o We suggest that when abdominal-perineal excision can be avoided, a standard low anterior resection is a reasonable option to treat rectal cancers in LS patients, even though the residual colon is at high-risk of metachronous neoplasia. (GRADE of evidence: low; Strength of recommendation: weak) o We recommend that gastric, small bowel, or pancreatic surveillance in LS patients is only performed in the context of a clinical trial. (GRADE of evidence: low; Strength

2019 British Society of Gastroenterology

40. New eUpdate featuring treatment algorithm for Early Colon Cancer

Breast/Ovarian Hereditary Cancer Syndromes Cancers of Unknown Primary Site Cancers of Unknown Primary Site Endocrine and Neuroendocrine Cancers Neuroendocrine Bronchial and Thymic Tumours • Neuroendocrine Gastroenteropancreatic Tumours • Adrenal Cancer • Thyroid Cancer Gastrointestinal Cancers Rectal Cancer • Biliary cancer • Gastric cancer • Oesophageal cancerCancer of the pancreas • Metastatic colorectal cancer • Anal cancer • Early colon cancer • Familial risk colorectal cancer • Hepatocellular (...) carcinoma Genitourinary Cancers Testicular Germ Cell CancerCancer of the Prostate • Bladder Cancer • Renal Cell Carcinoma • Penile Carcinoma • Testicular Seminoma and Non-Seminoma Gynaecological Cancers Cervical cancer • Endometrial cancer • Gestational trophoblastic disease • Newly diagnosed and relapsed epithelial ovarian carcinoma • Non-epithelial ovarian cancer • Ovarian Cancer Haematological Malignancies Waldenstrom's macroglobulinaemia • Chronic myeloid leukaemia • Newly diagnosed and relapsed

2019 European Society for Medical Oncology